Back to Search
Start Over
Bcr-Abl and inhibition of apoptosis in chronic myelogenous leukemia cells.
- Source :
-
Apoptosis : an international journal on programmed cell death [Apoptosis] 2000 Oct; Vol. 5 (4), pp. 315-8. - Publication Year :
- 2000
-
Abstract
- Chronic myelogenous leukemia (CML) cells are highly resistant to apoptosis induced by chemotherapeutic drugs. The observation that production of Bcr-Abl is the initiating event in CML has focussed attention on the survival signals triggered by this oncogene. A number of signal transducers and transcription factors have been associated with the antiapoptotic phenotype of CML cells, some of which lead to the expression and/or activation of members of the Bcl-2 family of apoptosis modulators, such as Bcl-xL and Bad. In this article, recent advances in understanding the antiapoptotic pathways triggered by Bcr-Abl in CML cells, are discussed.
- Subjects :
- DNA-Binding Proteins metabolism
Fusion Proteins, bcr-abl genetics
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive genetics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive metabolism
STAT5 Transcription Factor
Trans-Activators metabolism
Tumor Cells, Cultured
Apoptosis physiology
Fusion Proteins, bcr-abl metabolism
Leukemia, Myelogenous, Chronic, BCR-ABL Positive physiopathology
Milk Proteins
Signal Transduction
Subjects
Details
- Language :
- English
- ISSN :
- 1360-8185
- Volume :
- 5
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Apoptosis : an international journal on programmed cell death
- Publication Type :
- Academic Journal
- Accession number :
- 11227211
- Full Text :
- https://doi.org/10.1023/a:1009623222534